Mammalian target of rapamycin: A valid therapeutic target through the autophagy pathway for alzheimer's disease?
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Autophagy plays a critical role in multiple pathological lesions of Alzheimer's disease (AD), such as the formation of amyloid plaques from amyloid‐β (Aβ) production and accumulation via dysregulating amyloid precursor protein turnover and enhancing the activity of β‐ and/or γ‐secretases, intraneuronal neurofibrillary tangles (NFT) because of tau hyperphosphorylation, and neuronal apoptosis. Dysfunction of the autophagy‐lysosome system also contributes to Aβ accumulation and the formation of tau oligomers and insoluble aggregates, because induction of autophagy enhances the clearance of both soluble and aggregated forms of Aβ and tau proteins. The mammalian target of rapamycin (mTOR) pathway plays a central role in controlling protein homeostasis and negatively regulates autophagy. Inhibition of mTOR by rapamycin improves cognitive deficits and rescues Aβ pathology and NFTs by increasing autophagy. Several mTOR signaling components may be potential biomarkers of cognitive impairment in the clinical diagnosis of AD. Thus, mTOR‐related agents through the control of autophagy‐lysosome protein degradation are emerging as an important therapeutic target for AD. © 2012 Wiley Peridicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766 · cited 3×
“Preclinical data suggest that mTOR is involved in the regulation of life span and in age-related diseases, indicating that rapamycin inhibits mTORC1 activity and decreases protein biosynthesis and promotes autophagy activation, likely by a combination of increased autophagy and decreased mRNA translation (Tsang et al.…”
BackgroundLoss of autophagy in the central nervous system causes neurodegeneration in mice
Komatsu, M., Waguri, S., Chiba, T., Murata, S., Iwata, J.-I., Tanida, I., Ueno, T., Koike, M., Uchiyama, Y., Kominami, E., et al. (2006) · Nature · doi:10.1038/nature04723 · Cited by 3,500 · cited 3×
“Autophagy is essential in helping to maintain the balance between the increase and the decrease in the numbers of a cell population (Komatsu et al., 2006a; Wen et al., 2010).”
BackgroundJung, C. H., Ro, S.-H., Cao, J., Otto, N. M., & Kim, D.-H. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.01.017 · Cited by 2,090
Alzheimer’s disease β-amyloid peptides are released in association with exosomes
Rajendran, L., Honsho, M., Zahn, T. R., Keller, P., Geiger, K. D., Verkade, P., & Simons, K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603838103 · Cited by 1,343
Lee, J.-H., Yu, W. H., Kumar, A., Lee, S., Mohan, P. S., Peterhoff, C. M., Wolfe, D. M., Martinez-Vicente, M., Massey, A. C., Sovak, G., et al. (2010) · Cell · doi:10.1016/j.cell.2010.05.008 · Cited by 1,212 · cited 3×
“…a critical role in AD pathogenesis, involving the generation of multiple pathological lesions associated with AD, such as Ab production and deposition, NFT formation, and neuronal death (Zhang et al., 2009; Caccamo et al., 2010; Dolan and Johnson, 2010; Lee et al., 2010; J.F. Ma et al., 2010).”
BackgroundAutophagy mediates the mitotic senescence transition
Young, A. R. J., Narita, M., Ferreira, M., Kirschner, K., Sadaie, M., Darot, J. F. J., Tavaré, S., Arakawa, S., Shimizu, S., Watt, F. M., et al. (2009) · Genes & Development · doi:10.1101/gad.519709 · Cited by 1,078 · cited 1×
“Under nutrient-rich conditions, mTOR has an inhibitory effect on autophagy; under starvation conditions, mTOR is inactivated and leads to downstream dephosphorylation events resulting in transcriptional activation of autophagy genes (Vakana et al., 2010; Young et al., 2009).”
BackgroundSpilman, P., Podlutskaya, N., Hart, M. J., Debnath, J., Gorostiza, O., Bredesen, D., Richardson, A., Strong, R., & Galvan, V. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009979 · Cited by 1,033 · cited 3×
“…rapamycin rescues learning and memory deficits via inducing neuronal survival and plasticity and reduced Ab and tau pathology (Caccamo et al., 2010; Spilman et al., 2010; Santos et al., 2011), whereas dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in AD (T. Ma et al.,…”
BackgroundMacroautophagy—a novel β-amyloid peptide-generating pathway activated in Alzheimer's disease
Yu, W. H., Cuervo, A. M., Kumar, A., Peterhoff, C. M., Schmidt, S. D., Lee, J.-H., Mohan, P. S., Mercken, M., Farmery, M. R., Tjernberg, L. O., et al. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200505082 · Cited by 967 · cited 6×
“DOI: 10.1002/jnr.23011 ' 2012 Wiley Periodicals, Inc. Autophagy, a major pathway to lysosomes for the turnover of organelles and long-lived proteins, involves the sequestration and degradation of these cytoplasmic constituents within a series of vesicular compartments (autophagy vacuoles, or AVs; Yu et al., 2005; Bola…”
BackgroundInfluentialCleveland, D. W., Hwo, S.-Y., & Kirschner, M. W. (1977) · Journal of Molecular Biology · doi:10.1016/0022-2836(77)90213-3 · Cited by 915 · cited 1×
“Purification of tau induces assembly of microtubules (Cleveland et al., 1977).”
BackgroundMolecular Interplay between Mammalian Target of Rapamycin (mTOR), Amyloid-β, and Tau
Caccamo, A., Majumder, S., Richardson, A., Strong, R., & Oddo, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.100420 · Cited by 881
Tau protein pathology in neurodegenerative diseases
Spillantini, M. G., & Goedert, M. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01337-x · Cited by 683
Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing
Wang, Y., Martinez-Vicente, M., Krüger, U., Kaushik, S., Wong, E., Mandelkow, E.-M., Cuervo, A. M., & Mandelkow, E. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp367 · Cited by 617 · cited 6×
“There is evidence that dysfunction of the autophagy-lysosome system contributes to the formation of tau oligomers and insoluble aggregates (Hamano et al., 2008; Wang et al., 2009).”
BackgroundInfluentialTakei, N., Inamura, N., Kawamura, M., Namba, H., Hara, K., Yonezawa, K., & Nawa, H. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1427-04.2004 · Cited by 442 · cited 3×
“…and total protein synthesis is enhanced, in the learning hippocampus Mizuno et al., 2008; Morel et al., 2009a; Paccalin et al., 2006; Qi et al., 2010; Takei et al., 2004 *The upstream and downstream components of the mTOR signaling pathway are involved in a wide variety of AD pathogenic…”
BackgroundInfluentialYang, D.-S., Stavrides, P., Mohan, P. S., Kaushik, S., Kumar, A., Ohno, M., Schmidt, S. D., Wesson, D., Bandyopadhyay, U., Jiang, Y., et al. (2011) · Brain · doi:10.1093/brain/awq341 · Cited by 429
Li, X., Alafuzoff, I., Soininen, H., Winblad, B., & Pei, J. (2005) · The FEBS Journal · doi:10.1111/j.1742-4658.2005.04833.x · Cited by 324 · cited 3×
“The mTOR-dependent signaling pathway seems to be involved in AD patients’ brains as well as in AD models (An et al., 2003; Li et al., 2005; Pei and Hugon, 2008; Yoon et al., 2008).”
BackgroundChaperone-mediated autophagy in aging and disease
Massey, A. C., Zhang, C., & Cuervo, A. M. (2006) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(05)73007-6 · Cited by 315
An, W.-L., Cowburn, R. F., Li, L., Braak, H., Alafuzoff, I., Iqbal, K., Iqbal, I.-G., Winblad, B., & Pei, J.-J. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63687-5 · Cited by 312 · cited 2×
“The mTOR-dependent signaling pathway seems to be involved in AD patients’ brains as well as in AD models (An et al., 2003; Li et al., 2005; Pei and Hugon, 2008; Yoon et al., 2008).”
BackgroundRodríguez-Navarro, J. A., Rodríguez, L., Casarejos, M. J., Solano, R. M., Gómez, A., Perucho, J., Cuervo, A. M., García de Yébenes, J., & Mena, M. A. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.05.014 · Cited by 298
Hamano, T., Gendron, T. F., Causevic, E., Yen, S., Lin, W., Isidoro, C., DeTure, M., & Ko, L. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06084.x · Cited by 283
Yu, W. H., Kumar, A., Peterhoff, C., Shapiro Kulnane, L., Uchiyama, Y., Lamb, B. T., Cuervo, A. M., & Nixon, R. A. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.05.010 · Cited by 279
Ma, T., Hoeffer, C. A., Capetillo-Zarate, E., Yu, F., Wong, H., Lin, M. T., Tampellini, D., Klann, E., Blitzer, R. D., & Gouras, G. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012845 · Cited by 262
Role of the β‐amyloid protein in Alzheimer's disease
Sisodia, S. S., & Price, D. L. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.5.7896005 · Cited by 262
Genetic inactivation of p62 leads to accumulation of hyperphosphorylated tau and neurodegeneration
Ramesh Babu, J., Lamar Seibenhener, M., Peng, J., Strom, A., Kemppainen, R., Cox, N., Zhu, H., Wooten, M. C., Diaz‐Meco, M. T., Moscat, J., et al. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05340.x · Cited by 258 · cited 1×
“Journal of Neuroscience Research Alzheimer-like mouse model (Ramesh Babu et al., 2008), highlighting a novel role for p62 as a chaperone that regulates tau solubility, thereby preventing tau aggregation.”
BackgroundKuma, A., & Mizushima, N. (2010) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2010.03.002 · Cited by 237 · cited 1×
“Autophagy, a response to nutrient starvation and stress, is a housekeeping process whereby long-lived proteins and organelles, such as mitochondria, are recycled (Wu et al., 2009; Kuma and Mizushima, 2010).”
BackgroundLafay‐Chebassier, C., Paccalin, M., Page, G., Barc‐Pain, S., Perault‐Pochat, M. C., Gil, R., Pradier, L., & Hugon, J. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03187.x · Cited by 211
mTOR‐dependent signalling in Alzheimer's disease
Pei, J., & Hugon, J. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00509.x · Cited by 190
Caccamo, A., Majumder, S., Deng, J. J., Bai, Y., Thornton, F. B., & Oddo, S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.031278 · Cited by 169
Anthony, I. C., Norrby, K. E., Dingwall, T., Carnie, F. W., Millar, T., Arango, J. C., Robertson, R., & Bell, J. E. (2010) · Brain · doi:10.1093/brain/awq263 · Cited by 156 · cited 1×
“The disruption of the neuronal skeleton, as a result of hyperphosphorylation of tau and NFT formation, contributes to neuronal malfunction, neuronal cell death, and eventually AD (Arendt, 2004; Anthony et al., 2010; Fig.”
BackgroundCell “Self‐Eating” (Autophagy) Mechanism in Alzheimer's Disease
Funderburk, S. F., Marcellino, B. K., & Yue, Z. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20161 · Cited by 139
Kimball, S. R., Siegfried, B. A., & Jefferson, L. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410755200 · Cited by 133 · cited 1×
“…of the extracellular signal-regulated protein kinase 1-p90 signaling pathway; the LKB-AMPK signaling pathway is associated with the pathogenesis of AD Kimball et al., 2004; Rosner et al., 2008; Timm et al., 2008 Downstream S6K/S6 Mammalian target of rapamycin complex 1 (mTORC1) pathway,…”
BackgroundOxidative damage to the promoter region of SQSTM1/p62 is common to neurodegenerative disease
Du, Y., Wooten, M. C., & Wooten, M. W. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.015 · Cited by 96 · cited 1×
“It is also demonstrated that oxidative damage to the p62 promoter may be a causative contributor to tau hyperphosphorylation (Du et al., 2009a,b).”
BackgroundPaccalin, M., Pain-Barc, S., Pluchon, C., Paul, C., Besson, M.-N., Carret-Rebillat, A.-S., Rioux-Bilan, A., Gil, R., & Hugon, J. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000095562 · Cited by 96
Timm, T., Balusamy, K., Li, X., Biernat, J., Mandelkow, E., & Mandelkow, E.-M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706596200 · Cited by 95 · cited 1×
“…kinase 1-p90 signaling pathway; the LKB-AMPK signaling pathway is associated with the pathogenesis of AD Kimball et al., 2004; Rosner et al., 2008; Timm et al., 2008 Downstream S6K/S6 Mammalian target of rapamycin complex 1 (mTORC1) pathway, including p70(S6K) (the 70-kDa p70 S6 kinase) and…”
BackgroundWang, Y., Martinez-Vicente, M., Krüger, U., Kaushik, S., Wong, E., Mandelkow, E.-M., Cuervo, A. M., & Mandelkow, E. (2010) · Autophagy · doi:10.4161/auto.6.1.10815 · Cited by 90
APP and APLP1 are degraded through autophagy in response to proteasome inhibition in neuronal cells
Zhou, F., van Laar, T., Huang, H., & Zhang, L. (2011) · Protein & Cell · doi:10.1007/s13238-011-1047-9 · Cited by 63 · cited 5×
“, 2011), and blocking autophagy inhibits the expression of both APP and APLP1 (Zhou et al., 2011), indicating that it is a vital Ab-generating pathway through which APP/APLP1 is degraded through autophagy and APLP1 proteolysis is mediated mainly by the autophagy-lysosome pathway.”
BackgroundInfluentialPKR, the double stranded RNA‐dependent protein kinase as a critical target in Alzheimer's disease
Morel, M., Couturier, J., Lafay‐Chebassier, C., Paccalin, M., & Page, G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00849.x · Cited by 47 · cited 4×
“The mTOR signaling pathway is downregulated in cellular and animal models of AD (Yoon et al., 2008; Morel et al., 2009a).”
BackgroundInfluentialMorel, M., Couturier, J., Pontcharraud, R., Gil, R., Fauconneau, B., Paccalin, M., & Page, G. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.004 · Cited by 36 · cited 5×
“mTOR signaling components were tested as potential biomarkers of cognitive impairments in the clinical diagnosis of AD (Damjanac et al., 2008; Pei and Hugon, 2008; Morel et al., 2009b).”
BackgroundInfluentialDamjanac, M., Rioux Bilan, A., Paccalin, M., Pontcharraud, R., Fauconneau, B., Hugon, J., & Page, G. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.09.008 · Cited by 32 · cited 5×
“mTOR signaling components were tested as potential biomarkers of cognitive impairments in the clinical diagnosis of AD (Damjanac et al., 2008; Pei and Hugon, 2008; Morel et al., 2009b).”
BackgroundInfluentialDamjanac, M., Page, G., Ragot, S., Laborie, G., Gil, R., Hugon, J., & Paccalin, M. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00688.x · Cited by 31 · cited 2×
“…represent molecular links between the double- stranded RNA-dependent protein kinase (PKR) and the mTOR signalling pathways as a critical target in AD Damjanac et al., 2009; Kao et al., 2009; Morel et al., 2009a GTPase Signalling components upstream and downstream of the protein kinase mTOR are…”
Background
Cited by
Chen, Z., & Zhong, C. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.004 · Cited by 673
Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice
Ou, Z., Kong, X., Sun, X., He, X., Zhang, L., Gong, Z., Huang, J., Xu, B., Long, D., Li, J., et al. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.12.009 · Cited by 368
Self-citationPerluigi, M., Di Domenico, F., & Butterfield, D. A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.03.014 · Cited by 339
Xiao, Q., Yan, P., Ma, X., Liu, H., Perez, R., Zhu, A., Gonzales, E., Burchett, J. M., Schuler, D. R., Cirrito, J. R., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3788-13.2014 · Cited by 266
Wang, C., Zhang, X., Teng, Z., Zhang, T., & Li, Y. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.06.051 · Cited by 233
Metadata
- Authors
- Cai, Z., Zhao, B., Li, K., Zhang, L., Li, C., Quazi, S. H., & Tan, Y.
- Venue
- Journal of Neuroscience Research
- Publisher
- Wiley
- Published
- 2012-02-16
- Volume
- 90
- Issue
- 6
- Pages
- 1105-1118
- ISSN
- 0360-4012 (ISSN-L)
- 1097-4547
- OpenAlex
- W2059311496
- Cited by
- 134
- References
- 39
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.